The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
Report Scope
This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from the analyst's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for:- CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
- Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
- Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.
Reasons to Buy
- Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
- Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
- Learn about the past quarter’s M&A and financing deals in the manufacturing space.
- Identify the latest contract service agreements.
- Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
- Stay ahead of disruption with updates on supply chain obstacles and new regulations.
Table of Contents
- Industry Trends
- UK-US zero‑tariff deal and pricing reforms position UK as global hub for innovative medicines
- Trump administration sets deadline for pharma companies to fulfill MFN commitments
- Industry Analysis
- Contract service agreements
- Contract manufacturing - opportunities and threats
- Quarterly mergers, acquisitions, and financing - Q4 2025
- Value Chain
- Compounding
- API chemical
- API biologics - cell, gene, vaccine, and virus
- API biologics (protein and peptide)
- Commercial dose manufacturing and packaging
- Clinical dose manufacturing
- About the Analyst
- About the Authors
- Contact the Publisher
Table 1: Contract service agreements
Table 2: Contract manufacturing: opportunities and threats - potentially positive
Table 3: Contract manufacturing: opportunities and threats - potentially negative
Table 4: Mergers, acquisitions, and financing - Q4 2025
List of Figures
Figure 1: Contract service agreements by deal geography, by volume
Figure 2: Deals by deal geography, by volume - mergers, acquisitions, and financing
Figure 3: The contract manufacturing value chain
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Advent Bioservices Ltd
AGC Pharma Chemicals Europe SLU
Akadeum Life Sciences Inc
Alcami Corp
Almac Group Ltd
Alnylam Pharmaceuticals Inc
Alvogen Inc
Andelyn Biosciences Inc
Antheia Inc
Arthrosi Therapeutics Inc
AstraZeneca Pharmaceuticals LP
AstraZeneca Plc
AstraZeneca UK Ltd
Athlone Laboratories Ltd
ATUM
Astellas US LLC
A-Seeds Co Ltd
AAVantgarde Bio Srl
- Avid Bioservices Inc
Bayer USA LLC
Beigene USA Inc
BioCorRx Inc
BioCryst Pharmaceuticals Inc
BioLabs for Advanced Therapeutics Philadelphia
BioNTech
BioSpring GmbH
Boehringer Ingelheim Fremont Inc
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH & Co KG
Boehringer Ingelheim Pharmaceuticals
- Bora Pharmaceuticals Co Ltd
- Brenntag SE
- Catalent CTS LLC
Catalent Inc
Cell and Gene Therapy Catapult
Cellergy Therapeutics Ltd
Cellipont Bioservices
Cell Therapies Pty Ltd
- Charles River Laboratories International Inc
- CStone Pharmaceuticals Co Ltd
- Circurna
- CStone Pharmaceuticals Co Ltd
- CPC Scientific Inc
Coriolis Pharma Research GmbH
Curileum Discovery Ltd
Daiichi Sankyo Co Ltd
eXmoor Pharma Concepts Ltd
- EMD Serono (US)
- Encell Co Ltd
- Esteve Quimica SA
- FUJIFILM Cellular Dynamics Inc
Gazyvaro
- Genmab US Inc
- GRI Bio Operations Inc
Halo Pharma Inc
Hikma Pharmaceuticals Plc
Horizon Therapeutics USA Inc
IDT Biologika GmbH
Incyte Corp
INCOG BioPharma Services Inc
Infant Bacterial Therapeutics
Insmed Inc
Intrepid Labs
Ionetix Corp
- IVERIC bio Inc
- Johnson & Johnson
Janssen-Cilag International
- Kenai Therapeutics Inc
- Lifecore Biomedical LLC
Lotus US Financing
- Lonza Group Ltd
Merck & Co Inc
Merck Sharp & Dohme LLC
Mendus
Microsize
Minakem SAS
- Moderna
Novartis
- Novartis Gene Therapies
Organon & Co
- PCI Pharma Services
PharmaKorell GmbH
Pharmstandard
Pfizer Inc
Piramal Pharma Solutions Inc
Plasticell Ltd
ProBioGen AG
Quotient Sciences Ltd
Ratio Therapeutics Inc
Recipharm AB
Recordati UK Ltd
Rentschler Biopharma SE
- Repair Biotechnologies Inc
- Rinri Therapeutics Ltd
- Ronawk Inc
Samsung Biologics Co Ltd
Sandoz GmbH
- Schedio SA
Sistemic Ltd
- SmartCella Holding
StemSight Oy
Swedish Orphan Biovitrum
- Syenex Inc
- Telomir Pharmaceuticals Inc
Thermo Fisher Scientific Inc
Tivic Health Systems Inc
Tjoapack BV
Turbare Manufacturing LLC
TUV SUD AG
UBriGene Biosciences Inc
Vicebio Ltd
Vetter Pharma-Fertigung GmbH & Co KG
WuXi Biologics Co Ltd
WuXi STA
WuXi XDC Cayman Inc
Xellera Therapeutics Ltd
- Zhejiang Xianju Junye Pharmaceutical Co Ltd
